Emerging Markets Earnings Roundup: Sanofi Channel Stuffing In Brazil? (Part 4)
This article was originally published in PharmAsia News
Sanofi CEO Chris Viehbacher showed clear signs of disappointment during the company’s earnings call, admitting emerging markets under-performed, and revealing a debacle in Brazil that appears to be channel stuffing.
You may also be interested in...
Sanofi’s acquisition of Medley, Brazil’s largest generics company, reinforces its increasingly aggressive expansion in emerging markets.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.